Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Are we up today because of the ANVS results?
You are supposed to sell when that happens...not buy.
Now, it's up 8.58% for the day. How come?
Random walk of securities prices, a stock with little volume. Brownian motion.
In other words, no news, no reason to buy.
They can be fatal. Placebo effects can be positive or negative. The negative is easier to demonstrate.
https://en.wikipedia.org/wiki/Voodoo_death.
There was a case presented in one of my classes of man in WWII from one of the Caribbean islands where voodoo was practiced. The man was stationed in Asia in the British army. He received a letter saying that he had a death curse placed on him by a voodoo priest and that he would die on a particular time and day a few weeks in the future. The medical people tried to explain to him that it wasn't possible for a curse to kill him and he would be fine. He did not believe them. On the day in question he became very nervous and went to the medical people. They monitored him and tried to reassure him that he would be OK. As the appointed time approached his blood pressure started dropping and he died at the appointed time.
That is the negative side of the placebo effect, there have been examples of the positive side that are also very strong.
Wow, you can read AD tweets.
Wait for $2.70
Should I Buy Some?
Right now, AVXL is up 7.27%. Any reason for this? I've got a few dollars sitting in my brokerage account. Should I buy a few more AVXLs? Why? Why not?
The experts in biotech investing are all here. Let everyone know your thoughts, please.
[Oops. That was a few minutes ago. Now, it's up 8.58% for the day. How come?]
That had nothing to do with SAVA...both companies went up due to wall street bets on reddit. They losted them as meme stocks to attack short sellers.
About a furlong.
True of the active drug too. But one difference is that placebo may not affect biomarkers in the same way as the active drug for those given that.
And how long do placebo effects last?????
The placebo side effects are just as real as the effects.
Speak for yourself.
So far most of the time when he releases news the share price drops. So why do you think that releasing more news is going to change that pattern?
ANVS reported on a subset n of 90 using criteria that had not been pre-specified. So no, not pivotal, and not analogous to our 2b/3, either.
Got back in this morning at 3.52 . We just need something to squeeze some of the shorts . Hoping lol
Stock down almost 70%. Guess the lawsuits will be flying around and the CEO will be accused of everything short of murder.
surprising for ANVS imo....
the objective measure passed after only 3 months.
Poorly designed trial but the drug may still work...you can't really see any improvement in 3 months subjectively in AD
Well you had a chance to get out if you shorted at $31.50 Why are you here??
X from AF: He is so right about these scams, yet people blame him. It is the management who are scamming retailers with promised drugs, which are nothing but sugar pills with side effects. Additionally, there's always the placebo effect and issues with trial site compliance.
---------------------------------------------------
It's amazing -- and quite sad -- to see Alzheimer's disease attract the worst in biotech. $ANVS $BIVI $SAVA
Edited: $AVXL, too!
Patients exploited. Investors bamboozled.
-------------------------------------------------------------
All baby AD drug companies prove to be scams; they all pull similar stunts to get retailers excited, but then it all comes crashing down. BIVI pulled an unblinded gimmick, ANVS a subgroup of a subgroup, and AVXL is the king of such tactics. SAVA pulled a warrants stunt.
Any company delay data release, it is a clear indication of data mining and post-hoc end point to suit the narrative, biomarkers are another crazy thing these companies are coming up with.
Doc any thoughts on anvs results?
Seems like the issues for annovis is the analysis they did wasn't pre-specified, the fact it's only based on 12 weeks and the ADL fail (though less of a problem with new FDA guidance) plus quite low cash. Also noticed they had about 50% screened out from being in the trial (though I suppose no worse than the BP trials).
Annovis straight up recognises that a pivotal PIII trial is required!
Better for MCI. About the same for mild AD
I am sure there are people here with far more expertise that I, but I believe that Cog-13 is the preferred measure. It is my understanding that the two additional components are memory related, but would be interested in hearing from someone with more knowledge.
The stock is now down 38% and halted again. Looks like people are realizing they are no where near commercialization. EDIT - just reopened again and now down 48%.
COG-13 is a more sensitive (responsive) methodology than COG-11?
do you know why its trading so much lower. I think they didn't meet both endpoints but this was always touted as 1 of 2 phase 3s. The dose dependent improvement and biomarkers are very encouraging.
lol. You may be on to something.
Another small biotech just posted their phase 2/3 AD results. Annovis's trial is a useful comparison to ours. Note size, results, endpoints, disclosures. Also note timelines (eg LPLV mid-Feb). They have interesting things to say about their biomarkers.
Anavex or somebody should market the best ever placebo pill, the effect is real and has only imaginary side effects.
It is amazing how the mind can state influence the health of the rest of the body.
It’s a shame the placebo effect can’t be patented, but someone could claim new and effective methods of inducing it.
It is also worth noting, Ignatius, that they used ADAS Cog-11 versus the ADAS Cog-13 employed in the Anavex trial and the mAb trials.
Correction - ANVS now back down 15%. Ho hum.
ANVS reopened and is only down 5% now. AVXL is barely up. The market just doesn't care about AD.
They missed the endpoint in ADL CGIC and blamed the high placebo effect.
Yup. Get ready for some fireworks.
If they have good news it could spark a rally for AVXL...just like SAVA did three years ago. AVXL actually hit its highest SP of $31/share due to SAVA's good news.
Buckle up. This could go either way.
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
We both know how he exposes shareholders to unnecessary risk with his method.
Either we hit the targets in 2A/B or we didn't. You can put a shine on sheet. Release the data!
Nidan we all feel that lack of transparency is killing the stock
“This has really turned into a crap shoot!”
I agree with your first, second, third, fourth, fifth and seventh words.
You’ve decided to invest in Anavex knowing that it’s a speculative biotech and that you could lose your investment. I don’t have an issue with that. Good luck. But normalizing Missling and basically saying he’s no different than other biotech CEOs, or blaming Adam Feuerstein and hedge funds, is wrong. Missling’s track record, which I’ve urged you to spend some time reviewing, is not just like any other CEO. Confirmation bias to justify an investment is a recipe to lose money. Please do yourself a favor and study Missling’s work history prior to Anavex and his track record since joining Anavex. If you look over his work history you’ll see that he rarely spent more than a year in any job. He was also a senior executive at an investment bank that was shut down by the SEC. In some instances he lasted just a few months. Don’t take my word for it. You can Google it. With some effort, you’ll find it. If you do that, I think you will see that Missling is at the tail end of the bell curve when it comes to CEO performance. It’s one of the reasons I believe he should be replaced.
Again, I’m not saying don’t invest. I’m simply telling you to at least get a clearer picture of who you’ve entrusted with your money.
He's no different than most CEO's in that way, most quarterlies are scheduled on or near the last day they're supposed to report. I live in L.A., decades ago most quarterly and other presentations were scheduled about a half hour after the market closed. Suddenly I found most companies switching to an hour or so before the open. I asked my broker what was going on and the explanation was simple, nearly all the Analysts are on the East Coast and nearly all come in well before the bell to get up to date on the news. They complained that when the day ended they wanted to leave, not wait around for nearly two hours to first read the financial, then listen to the quarterly report which followed the release.
While I'm interested, I don't get up at 5 a.m. to see the release, or 5:30 to hear the call, and only rarely am up when the market opens at 6:30 my time. I may use the bathroom about then, so I'll take a glance, but unless I find a big move in one or more of my stocks I just go back to bed until I normally wake up, 1 to 3 hours later. One of these days, if I miss the open, when I do wake up I'll learn I'm half a million or more dollars richer, from NWBO news, I don't own enough AVXL to make that sort of gain, at least not yet.
Gary
Missling is sloppy with his timing. He doesn’t think when he picks dates for CCs. Several times he had CCs on strange dates like before holidays and weird times like switching to an 8am on a Monday, not thinking investors read into these moves.
They all have been a nothing burger, while we all got excited expecting something since he telegraphed.
I hope there’s something here this time.
Or maybe he was just like, oh crap, we got to do the ASM. Shiit, I knew I should have never fired my secretary.
Followers
|
1065
|
Posters
|
|
Posts (Today)
|
48
|
Posts (Total)
|
457883
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |